Catalog No.
RHC88202
Species reactivity
Human, Mouse
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
FCM: 1:200-1:400, IF: 1:100-1:400, WB: 1:500-1:2000
Target
DNA topoisomerase 1, TOP1, DNA topoisomerase I
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11387
Applications
FCM, IF, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3C59
A Rare Case of Systemic Sclerosis with Topo I Positivity and Anti-Topoisomerase I (Scl-70) Antibody Negativity., PMID:40387758
HER2-targeted star polymer conjugates for improved tumor distribution and efficacy., PMID:40122243
TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs., PMID:40095530
Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy., PMID:40082588
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734
Application of a bivalent "click" approach to target tyrosyl-DNA phosphodiesterase 1 (TDP1)., PMID:39990162
Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition., PMID:39874630
OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models., PMID:39786401
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer., PMID:39745368
Fluorescence-activated nuclear sorting (FANS) of nuclei from in vitro-generated syncytiotrophoblast., PMID:38944560
Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation., PMID:38759301
Levels of anti-topoisomerase I antibody correlated with short onset of cardiopulmonary involvement in Thai systemic sclerosis patients., PMID:38710779
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer., PMID:38709212
Detection of IgE-autoantibodies to nuclear antigens in patients with systemic sclerosis and analysis of their clinical relevance., PMID:38530662
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair., PMID:38383600
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC., PMID:38369013
Flexible protein-protein docking with a multitrack iterative transformer., PMID:38148272
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response., PMID:37913680
Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates., PMID:37828728
Isolation and Immunodetection of Enzymatic DNA-Protein Crosslinks by RADAR Assay., PMID:37574479
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan., PMID:37567892
Ago2 and a miRNA reduce Topoisomerase 1 for enhancing DNA cleavage in antibody diversification by activation-induced cytidine deaminase., PMID:37094168
Necessity of HuR/ELAVL1 for the activation-induced cytidine deaminase-dependent decrease in topoisomerase 1 in antibody diversification., PMID:37086201
New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads., PMID:36637483
Antigen-independent tumor targeting by CBX-12 (alphalex™-exatecan) induces long-term antitumor immunity., PMID:36597724
Bifunctional G-Quadruplex Aptamer Targeting Nucleolin and Topoisomerase 1: Antiproliferative Activity and Synergistic Effect of Conjugated Drugs., PMID:36516871
The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates., PMID:36015333
TOP1 CAD-seq: A protocol to map catalytically engaged topoisomerase 1 in human cells., PMID:35942340
Highly Purified Top1-Bound DNA Fragments., PMID:35704193
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor., PMID:35439320
Topoisomerase I inhibitors: Challenges, progress and the road ahead., PMID:35413618
Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA., PMID:34956217
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer., PMID:34404686
Combining multi-antigenic immunodot with indirect immunofluorescence on HEp-2 cells improves the diagnosis of systemic sclerosis., PMID:34111525
Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2+ Breast Cancer Cells., PMID:33809102
Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype., PMID:33490922
A patent review of topoisomerase I inhibitors (2016-present)., PMID:33475439
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer., PMID:32847480
Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc-related autoantibodies: A single-center retrospective study., PMID:32662135
Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1)., PMID:32460231
Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma., PMID:32162841
A specific autoantibody against a novel tumour-association antigen derived from human DNA-topoiomerase I is a potential biomarker for early diagnosis and favourable prognosis in patients with colorectal carcinoma., PMID:31922440
An autoantibody against a 48-Kd fragment of human DNA-topoiomerase I in breast cancer: Implication for diagnosis and prognosis, and antibody-dependent cellular cytotoxicity in vitro., PMID:31732123
Enzymatic activity in single cells., PMID:31668235
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions., PMID:31602296
High-throughput sequencing analysis of genes encoding the B-lymphocyte receptor heavy-chain CDR3 in renal and peripheral blood of IgA nephropathy., PMID:31551340
The Nuclear Matrix Protein SAFA Surveils Viral RNA and Facilitates Immunity by Activating Antiviral Enhancers and Super-enhancers., PMID:31513772
Nitidine chloride exerts anti-inflammatory action by targeting Topoisomerase I and enhancing IL-10 production., PMID:31415918
Targeting Topoisomerase I in the Era of Precision Medicine., PMID:31227499
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene., PMID:31196001
For research use only. Not for human or drug use.
